Publication:
Long term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy

Simple item page
dc.conference.dateDEC 10-13, 2022
dc.conference.location64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)
dc.conference.locationNew Orleans, LA
dc.contributor.coauthorNorthend, Michael
dc.contributor.coauthorWilson, William
dc.contributor.coauthorClifton-Hadley, Laura
dc.contributor.coauthorRana, Zaynab
dc.contributor.coauthorMartin, Tanya-Louise
dc.contributor.coauthorYoung, Moya
dc.contributor.coauthorMiall, Fiona
dc.contributor.coauthorCunningham, David
dc.contributor.coauthorWalewski, Jan
dc.contributor.coauthorJohnston, Amanda
dc.contributor.coauthorSeymour, John F.
dc.contributor.coauthorLinch, David C.
dc.contributor.coauthorArdeshna, Kirit M.
dc.contributor.departmentSchool of Medicine
dc.contributor.facultymemberYes
dc.contributor.kuauthorFerhanoğlu, Ahmet Burhan
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:07:47Z
dc.date.issued2022
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.openaccessYES
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.studentonlypublicationNo
dc.description.studentpublicationNo
dc.description.versionN/A
dc.identifier.doi10.1182/blood-2022-156790
dc.identifier.eissn1528-0020
dc.identifier.embargoN/A
dc.identifier.endpage1458
dc.identifier.issn0006-4971
dc.identifier.quartileQ1
dc.identifier.startpage1456
dc.identifier.urihttps://doi.org/10.1182/blood-2022-156790
dc.identifier.urihttps://hdl.handle.net/20.500.14288/9203
dc.identifier.volume140
dc.identifier.wos000893223201193
dc.keywordsFollicular lymphoma
dc.keywordsRituximab
dc.keywordsWatchful waiting
dc.language.isoeng
dc.publisherAmerican Society of Hematology (ASH)
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofBlood
dc.relation.openaccessN/A
dc.rightsN/A
dc.subjectHematology
dc.titleLong term follow-up of international randomised phase 3 study of rituximab versus a watch and wait approach for patients with asymptomatic, low tumour burden follicular lymphoma shows rituximab is highly effective at delaying time to new treatment without detrimental impact following next line of therapy
dc.typeMeeting Abstract
dspace.entity.typePublication
local.contributor.kuauthorFerhanoğlu, Ahmet Burhan
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext